I. AMENDMENTS TO THE CLAIMS

This listing of claims shall replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-37. (cancelled)

38. (currently amended): A method of effectively treating pain in humans comprising orally administering to a human patient an oral dosage form comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of

(i) meloxicam and/or at least one pharmaceutically acceptable salt thereof; and

(ii) oxycodone and/or at least one pharmaceutically acceptable salt thereof;

wherein the meloxicam and/or at least one pharmaceutically acceptable salt thereof is present in the oral dosage form in an amount from about 0.5 mg to about 1500 mg;

wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof is present in the oral dosage form in an amount from 2.5 mg to 800 mg;

wherein said dosage form comprises a sustained release carrier in an amount such that said oral dosage form provides a therapeutic effect for about 12 hours or longer.

39- 46. (cancelled)

47. (previously presented) The method of claim 38, wherein the ratio of oxycodone and/or at least one pharmaceutically acceptable salt thereof to meloxicam and/or at least one pharmaceutically acceptable salt thereof is from about 0.0001:1 to about 1:1.

48. (previously presented) The method of claim 38, wherein the oxycodone is present in the pharmaceutically acceptable salt form.

49-52 (cancelled)

53. (new) The method of claim 38, wherein said sustained release carrier is selected from the group consisting of an alkylcellulose; a hydroxyalkylcellulose; an acrylic polymer; a fatty acid; a fatty alcohol; a glyceryl ester of fatty acids; a mineral oil or wax; a vegetable oil or wax; a polyalkylene glycol; shellac; zein; and mixtures of any of the foregoing.

54. (new) The method of claim 38, wherein said pain is cancer pain, post-surgical pain, low back and neck pain, dysmenorrheal, headache, toothache, pain from sprains and strains, myositis, neuralgia, synovitis, arthritis, degenerative joint diseases, gout and ankylosing spondylitis, bursitis, burns, injuries, influenza or other viral infections, and common cold.

55. (new) A method of effectively treating moderate to severe pain in humans comprising

orally administering to a human patient an oral dosage form comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of

(i) meloxicam and/or at least one pharmaceutically acceptable salt thereof; and

(ii) oxycodone and/or at least one pharmaceutically acceptable salt thereof;

wherein said dosage form comprises (a) said meloxicam in immediate release form and (b) said oxycodone in sustained release form, said oral dosage form further comprising a sustained release carrier in an amount such that said oral dosage form provides a therapeutic effect of said oxycodone for at least 12 hours or longer.

56. (new) The method of claim 55, wherein said sustained release carrier is selected from the group consisting of an alkylcellulose; a hydroxyalkylcellulose; an acrylic polymer; a fatty acid; a fatty alcohol; a gylceryl ester of fatty acids; a mineral oil or wax; a vegetable oil or wax; a polyalkylene glycol; shellac; zein; and mixtures of any of the foregoing.

57. (new) The method of claim 55, wherein said pain is cancer pain, post-surgical pain, low back and neck pain, dysmenorrheal, headache, toothache, pain from sprains and

strains, myositis, neuralgia, synovitis, arthritis, degenerative joint diseases, gout and ankylosing spondylitis, bursitis, burns, injuries, influenza or other viral infections, and common cold.

58. (new) The method of claim 55, wherein said dosage form comprises particles, wherein said particles have diameter from about 0.1 mm to about 2.5 mm.

59. (new) The method of claim 58, wherein said particles have diameter from about 0.5 mm to about 2 mm.

60. (new) The method of claim 55, wherein the meloxicam is coated onto a tablet comprising oxycodone in sustained release form.

61 (new) The method of claim 55, wherein said sustained release carrier being (i) a sustained release coating; or (ii) incorporated into a matrix with said oxycodone.

62. (new) The method of claim 55, wherein said oral dosage form provides a therapeutic effect of said oxycodone for about 24 hours.